A drug approved to treat rheumatoid arthritis, tocilizumab (Actemra, Genentech), is a potential new therapy for patients with polymyalgia rheumatica, according to an open-label, phase II study presented at the annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals on November 10. The inflammatory disorder impacts 1% of people over the age of 50 and is predominantly found in inpiduals over the age of 65.
Source: Medical Xpress